The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma

March 27, 2026 updated by: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
This project will target patients with histopathologically diagnosed mucosal melanoma using [¹⁸F]FDG PET/CT imaging for retrospective prognostic evaluation.The primary objective is to explore the value of [¹⁸F]FDG PET/CT imaging in the prognostic assessment of mucosal melanoma, and to determine the correlations between quantitative [¹⁸F]FDG PET parameters and progression-free survival (PFS) as well as overall survival (OS), so as to provide reference evidence for individualized treatment decision-making.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

68

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Wuhan Union Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

We reviewed the electronic medical record and imaging data of patients with pathologically confirmed mucosal melanoma who underwent [18F]FDG PET/CT imaging at the PET Center of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 1, 2021 and June 1, 2024.

Description

Inclusion Criteria:

  1. Patients with histopathologically confirmed mucosal melanoma.

Exclusion Criteria:

  1. Having another primary malignancy (other than mucosal melanoma).
  2. Being lost to follow-up.
  3. Being under 18 years of age.
  4. Being pregnant or breastfeeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Mucosal Melanoma Cohort
Retrospective cohort of mucosal melanoma patients who underwent [18F]FDG PET/CT for prognostic evaluation.
Other: Telephone follow-up
Telephone follow-up

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival
Time Frame: Up to 4 years
Overall survival (OS) is defined as the time elapsed from the date of the ¹⁸F-FDG PET/CT examination to the date of death.
Up to 4 years
Progression-free survival
Time Frame: Up to 4 years
Progression-free survival (PFS) is defined as the time from the date of [18F]FDG PET/CT imaging to the earliest date of disease progression, recurrence, or death.
Up to 4 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Actual)

May 8, 2025

Study Completion (Actual)

March 13, 2026

Study Registration Dates

First Submitted

March 16, 2026

First Submitted That Met QC Criteria

March 27, 2026

First Posted (Actual)

April 1, 2026

Study Record Updates

Last Update Posted (Actual)

April 1, 2026

Last Update Submitted That Met QC Criteria

March 27, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • XLan-251264

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mucosal Melanoma

Clinical Trials on Telephone follow-up

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe